Articles published by Regeneron Pharmaceuticals, Inc.Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
Via GlobeNewswire
Tickers
REGN
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
Via GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
February 06, 2024
Via GlobeNewswire
Tickers
REGN
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 02, 2024
Via GlobeNewswire
Tickers
REGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
Penticton Herald
Phone number: 250-492-4002
E-mail: csr@ok.bc.ca
Address: 186 Nanaimo Ave. W.
Penticton, BC V2A 1N4
© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.